.Attributes Medicine, Posted online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- drug conjugate (ADC) tisotumab vedotin resulted in strengthened progression-free as well as general survival, bring about FDA approval and also a new therapy alternative for patients.